Treating Duchenne means hope to
share meaningful moments

Jordan (14 years old), a real VILTEPSO patient and compensated spokesperson, and his mother, Laura

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping. Accelerated approval is based on an increase in dystrophin. There is an ongoing study to confirm the clinical benefit of VILTEPSO.

Caregiver Icon

If you are aHEALTHCARE PROVIDERwho treats patients with DMD

Learn More
Boy Icon

If you are aPATIENT or a CAREGIVERof a person with DMD

Discover VILTEPSO
Infusion Icon

If you areLOOKING FOR SUPPORT and RESOURCES

Get Information

Providing personalized access support and customized resources

NS Pharma is fully committed to providing ongoing support to DMD patients, their caregivers, and healthcare professionals.

Learn About NS Support
Prescribing Information
News Release
Stay Informed
Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

For more information about VILTEPSO, see full Prescribing Information.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.